162 related articles for article (PubMed ID: 12582329)
1. Topical immunopharmacology of ocular allergies.
Bielory L; Kempuraj D; Theoharides T
Curr Opin Allergy Clin Immunol; 2002 Oct; 2(5):435-45. PubMed ID: 12582329
[TBL] [Abstract][Full Text] [Related]
2. Olopatadine: a drug for allergic conjunctivitis targeting the mast cell.
Leonardi A; Quintieri L
Expert Opin Pharmacother; 2010 Apr; 11(6):969-81. PubMed ID: 20307221
[TBL] [Abstract][Full Text] [Related]
3. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM
Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic options in ocular allergic disease.
Hingorani M; Lightman S
Drugs; 1995 Aug; 50(2):208-21. PubMed ID: 8521755
[TBL] [Abstract][Full Text] [Related]
5. Overview of ocular allergy treatment.
Friedlaender M
Curr Allergy Asthma Rep; 2001 Jul; 1(4):375-9. PubMed ID: 11892061
[TBL] [Abstract][Full Text] [Related]
6. The clinical spectrum of ocular allergy.
Brémond-Gignac D
Curr Allergy Asthma Rep; 2002 Jul; 2(4):321-4. PubMed ID: 12044268
[TBL] [Abstract][Full Text] [Related]
7. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies.
Anderson DF
Clin Exp Allergy; 2001 Jun; 31(6):823-6. PubMed ID: 11422145
[No Abstract] [Full Text] [Related]
8. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research.
Rosenwasser LJ; O'Brien T; Weyne J
Curr Med Res Opin; 2005 Sep; 21(9):1377-87. PubMed ID: 16197656
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulators for conjunctivitis.
Pacharn P; Vichyanond P
Curr Opin Allergy Clin Immunol; 2013 Oct; 13(5):550-7. PubMed ID: 23974685
[TBL] [Abstract][Full Text] [Related]
10. Multiple action agents and the eye: do they really stabilize mast cells?
Lambiase A; Micera A; Bonini S
Curr Opin Allergy Clin Immunol; 2009 Oct; 9(5):454-65. PubMed ID: 19652595
[TBL] [Abstract][Full Text] [Related]
11. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
12. Topical Antihistamines and Mast Cell Stabilizers for Treating Allergic Conjunctivitis.
Mounsey AL; Gray RE
Am Fam Physician; 2016 Jun; 93(11):915-6. PubMed ID: 27281835
[No Abstract] [Full Text] [Related]
13. Treatment with galectin-1 eye drops regulates mast cell degranulation and attenuates the severity of conjunctivitis.
Mello-Bosnic C; Gimenes AD; Oliani SM; Gil CD
Eur J Pharmacol; 2018 Aug; 833():124-130. PubMed ID: 29859836
[TBL] [Abstract][Full Text] [Related]
14. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans.
Leonardi A; Abelson MB
Clin Ther; 2003 Oct; 25(10):2539-52. PubMed ID: 14667955
[TBL] [Abstract][Full Text] [Related]
15. Ocular anti-allergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo.
Galatowicz G; Ajayi Y; Stern ME; Calder VL
Clin Exp Allergy; 2007 Nov; 37(11):1648-56. PubMed ID: 17877767
[TBL] [Abstract][Full Text] [Related]
16. Time to manage seasonal ocular allergies.
Smith SE
J Ophthalmic Nurs Technol; 2000; 19(2):68-73. PubMed ID: 11075076
[No Abstract] [Full Text] [Related]
17. What is the most effective topical treatment for allergic conjunctivitis?
Schulz S; Adam P
J Fam Pract; 2015 May; 64(5):315, 21. PubMed ID: 26009742
[No Abstract] [Full Text] [Related]
18. Update on ocular allergy treatment.
Bielory L
Expert Opin Pharmacother; 2002 May; 3(5):541-53. PubMed ID: 11996633
[TBL] [Abstract][Full Text] [Related]
19. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents.
Kimchi N; Bielory L
Curr Opin Allergy Clin Immunol; 2020 Aug; 20(4):414-420. PubMed ID: 32558665
[TBL] [Abstract][Full Text] [Related]
20. Topical cyclosporine inhibits mast cell-mediated conjunctivitis.
Whitcup SM; Chan CC; Luyo DA; Bo P; Li Q
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2686-93. PubMed ID: 8977483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
